中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 5
May  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(5): 1003-1008

Mechanism of bis（2-ethylhexyl） phthalate in inducing cholestasis and liver injury in mice

DOI: 10.12449/JCH240521
  • 1.

    Department of Pharmacy，Anhui Medical University，Hefei 230032，China

  • 2.

    Department of Pharmacy，The First Affiliated Hospital of Anhui Medical University，Hefei 230012，China

  • 3.

    Anhui Public Health Clinical Center，Hefei 230012，China

Research funding:

National Natural Science Foundation of China (82073566);

The Program of Excellent Young Talents in Universities of Anhui Province (gxyq2019014);

Clinical Pharmacy and Pharmacology (2020);

Anhui Public Health Clinical Center Supported by North District Scientific Research and Cultivation Foundation of the First Affiliated Hospital of Anhui Medical University (2023YKJ14);

Anhui Public Health Clinical Center Supported by North District Scientific Research and Cultivation Foundation of the First Affiliated Hospital of Anhui Medical University (2023YKJ06);

Anhui Public Health Clinical Center Supported by North District Scientific Research and Cultivation Foundation of the First Affiliated Hospital of Anhui Medical University (2023YKJ11)

More Information
  • Corresponding author: WANG Jianqing， jianqingwang81@126.com （ORCID： 0000-0002-7935-9520）
  • Received Date: 2023-08-09
  • Accepted Date: 2023-09-11
  • Published Date: 2024-05-25
    Abstract
  •   Objective  To investigate the mechanism of bis（2-ethylhexyl） phthalate （DEHP） in inducing cholestasis and liver injury in mice.  Methods  In the in vivo experiment， adult female ICR mice were randomly divided into control group （corn oil） and DEHP group （200 mg/kg/d）， and a model of cholestasis was established by intragastric administration for 4 weeks. After blood and liver tissue samples were collected from all mice， a biochemical analyzer was used to measure the level of total bile acid （TBA） in serum and the liver， and a microplate reader was used to measure alkaline phosphatase （ALP） and gamma-glutamyl transpeptidase （GGT）； HE staining was used to observe the pathological changes of the liver； RT-PCR was used to measure the mRNA expression levels of the inflammatory factors interleukin-1β （IL-1β）， interleukin-6 （IL-6）， and tumor necrosis factor-α （TNF-α） in the liver； liquid chromatography/triple quadrupole mass spectrometry was used to measure the bile acid profile in the liver of mice. In the invitro experiment， AML-12 mouse hepatocytes were cultured and treated with DEHP （250 µmol/L）， DCA （125 µmol/L）， and CDCA （125 µmol/L） for 24 hours， and RT-PCR was used to measure the mRNA expression levels of the inflammatory cytokines IL-1β， IL-6， and TNF-α. The independent-samples t test was used for comparison of continuous data between two groups； a one-way analysis of variance was used for comparison between multiple groups， and the LSD-t test was used for further comparison between two groups.  Results  The invivo experiment showed that compared with the control group， the DEHP group had significant increases in the serum levels of TBA， ALP， and GGT and the level of TBA in the liver （the t values are respectively -4.396， -5.109， -8.504， -3.792 and -7.974， all P<0.05，）. Compared with the control group， the DEHP group had significant increases in cholic acid， chenodeoxycholic acid， taurocholic acid， deoxycholic acid， and ursodeoxycholic acid （the t values are respectively -2.802， -3.177， -2.633， -2.874 and -2.311， all P<0.05）. HE staining of the liver showed that the mice in the DEHP group had enlargement of the portal area， bile duct deformation， inflammatory cell infiltration around the bile duct， and significant increases in the mRNA expression levels of the inflammatory factors IL-1β， IL-6， and TNF-α in the liver （the t values are respectively -2.539， -2.823 and -4.636， all P<0.05）. The invitro experiment showed that the actual difference in hepatocyte viability after 0-1 000 µmol/L DEHP treatment does not exceed 15%， but there were significant increases in the mRNA expression levels of the inflammatory cytokines IL-1β， IL-6， and TNF-α after treatment with DEHP at different concentrations of 125 µmol/L， 250 µmol/L， and 500 µmol/L （all P<0.05）. Compared with DEHP stimulation alone， the combined stimulation of CDCA and DEHP upregulates the cytokine in hepatocyte IL-1β mRNA levels （P<0.01）； the combined stimulation of DCA and DEHP can significantly increase the cytokine in hepatocyte IL-1β and IL-6 mRNA levels （all P<0.01）.  Conclusion  DEHP exposure can cause cholestasis and induce liver inflammation in mice， possibly by promoting the production of toxic bile acids and the secretion of inflammatory factors.

     

    • FullText(HTML)
    • References(12)
  • [1]
    CHIANG JYL, FERRELL JM. Discovery of farnesoid X receptor and its role in bile acid metabolism[J]. Mol Cell Endocrinol, 2022, 548: 111618. DOI: 10.1016/j.mce.2022.111618.
    [2]
    FANG D, LI PY. The treatment of cholestasis[J]. J Crit Care Intern Med, 2020, 26( 1): 22- 24. DOI: 10.11768/nkjwzzzz20200106.

    方丹, 黎培员. 胆汁淤积的治疗[J]. 内科急危重症杂志, 2020, 26( 1): 22- 24. DOI: 10.11768/nkjwzzzz20200106.
    [3]
    LI X, HAN XX, VOGT RD, et al. Polyethylene terephthalate and di-(2-ethylhexyl) phthalate in surface and core sediments of Bohai Bay, China: Occurrence and ecological risk[J]. Chemosphere, 2022, 286( Pt 3): 131904. DOI: 10.1016/j.chemosphere.2021.131904.
    [4]
    BAGEL S, DESSAIGNE B, BOURDEAUX D, et al. Influence of lipid type on bis(2-ethylhexyl)phthalate(DEHP) leaching from infusion line sets in parenteral nutrition[J]. JPEN J Parenter Enteral Nutr, 2011, 35( 6): 770- 775. DOI: 10.1177/0148607111414021.
    [5]
    GAITANTZI H, HAKENBERG P, THEOBALD J, et al. Di(2-ethylhexyl) phthalate and its role in developing cholestasis: An invitro study on different liver cell types[J]. J Pediatr Gastroenterol Nutr, 2018, 66( 2): e28- e35. DOI: 10.1097/MPG.0000000000001813.
    [6]
    QU MC, ZHAO F, ZHANG C, et al. Protective effect of obeticholic acid on cholestasis induced by subacute exposure to DEHP in mice[J]. Acta Univ Med Anhui, 2022, 57( 10): 1608- 1613. DOI: 10.19405/j.cnki.issn1000-1492.2022.10.018.

    屈明超, 赵凡, 张程, 等. 奥贝胆酸对DEHP亚急性暴露导致小鼠胆汁淤积的保护作用[J]. 安徽医科大学学报, 2022, 57( 10): 1608- 1613. DOI: 10.19405/j.cnki.issn1000-1492.2022.10.018.
    [7]
    PREECE AS, SHU H, KNUTZ M, et al. Indoor phthalate exposure and contributions to total intake among pregnant women in the SELMA study[J]. Indoor Air, 2021, 31( 5): 1495- 1508. DOI: 10.1111/ina.12813.
    [8]
    ZHANG YX, HUANG B, HE H, et al. Urinary phthalate metabolites among workers in plastic greenhouses in Western China[J]. Environ Pollut, 2021, 289: 117939. DOI: 10.1016/j.envpol.2021.117939.
    [9]
    ZHANG JY, WANG JQ. Research advances in the impact of phthalates on cholestatic liver disease[J]. J Clin Hepatol, 2023, 39( 1): 226- 230. DOI: 10.3969/j.issn.1001-5256.2023.01.035.

    张佳怡, 王建青. 邻苯二甲酸酯对胆汁淤积性肝病影响的研究进展[J]. 临床肝胆病杂志, 2023, 39( 1): 226- 230. DOI: 10.3969/j.issn.1001-5256.2023.01.035.
    [10]
    Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of cholestasis liver diseases(2015)[J]. J Clin Hepatol, 2015, 31( 12): 1989- 1999.

    中华医学会肝病学分会, 中华医学会消化病分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31( 12): 1989- 1999.
    [11]
    GOURLAY T, SAMARTZIS I, STEFANOU D, et al. Inflammatory response of rat and human neutrophils exposed to di-(2-ethyl-hexyl)-phthalate-plasticized polyvinyl chloride[J]. Artif Organs, 2003, 27( 3): 256- 260. DOI: 10.1046/j.1525-1594.2003.07107.x.
    [12]
    SONG PZ, ZHANG YC, KLAASSEN CD. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice[J]. Toxicol Sci, 2011, 123( 2): 359- 367. DOI: 10.1093/toxsci/kfr177.
    • Relative Articles

  • Relative Articles

    [1]Jiping ZHANG. Pathological diagnosis of cholestatic liver disease[J]. Journal of Clinical Hepatology, 2024, 40(6): 1093-1099. doi: 10.12449/JCH240605
    [2]Xiaoxuan XIE, Lina DU, Ziyun GUO, Yan YANG. Role of apical sodium-dependent bile acid transporter in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2024, 40(1): 199-203. doi: 10.12449/JCH240133
    [3]Mengzhen HOU, Yun YU, Qianqian HUANG, Lun ZHANG, Wenkang TAO, Yue JIANG, Jianqing WANG. Protective effect of folic acid against cholestatic liver injury in mice caused by bis（2-ethylhexyl） phthalate exposure[J]. Journal of Clinical Hepatology, 2024, 40(10): 2062-2069. doi: 10.12449/JCH241021
    [4]Xiaoming WU, Qiang HE, Linyi HOU, Yan HU, Xiaofang ZHEN, Jing HAO, Yan SHENG. Effect of Yudantong decoction on intestinal flora and intestinal barrier function in mice with cholestasis induced by α-naphthyl isothiocyanate[J]. Journal of Clinical Hepatology, 2023, 39(4): 864-875. doi: 10.3969/j.issn.1001-5256.2023.04.018
    [5]Yuanqin DU, Meng WANG, Guochu HUANG, Chun YAO, Ruixi ZHONG, Liangjiang HUANG, Jian XU, Jingjing HUANG, Qinwen TAN, Dewen MAO. Therapeutic effect of retention enema with compound rhubarb decoction on a rat model of minimal hepatic encephalopathy based on bile acid metabolomics[J]. Journal of Clinical Hepatology, 2023, 39(10): 2348-2357. doi: 10.3969/j.issn.1001-5256.2023.10.012
    [6]Jiayi ZHANG, Jianqing WANG. Research advances in the impact of phthalates on cholestatic liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 226-230. doi: 10.3969/j.issn.1001-5256.2023.01.035
    [7]Jing LI, Kuiyang ZHENG, Beibei ZHANG. Mechanism of action of bile acid metabolism in regulating cholestatic liver disease and the research and development of drugs[J]. Journal of Clinical Hepatology, 2021, 37(10): 2482-2487. doi: 10.3969/j.issn.1001-5256.2021.10.048
    [8]Kan YanTing, Yang YongFeng. Role of cholestatic liver disease-related genes in intrahepatic cholestasis of pregnancy[J]. Journal of Clinical Hepatology, 2019, 35(7): 1439-1443. doi: 10.3969/j.issn.1001-5256.2019.07.006
    [9]Jia HaoYu, Yang ZhangQing. The role of enterohepatic circulation of bile acids and intestinal microbiota in the pathogenesis and treatment of cholestatic liver disease[J]. Journal of Clinical Hepatology, 2019, 35(2): 270-274. doi: 10.3969/j.issn.1001-5256.2019.02.007
    [10]Du LiNa, Yang Yan. Establishment and application of animal models of cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 444-447. doi: 10.3969/j.issn.1001-5256.2019.02.046
    [11]Shen Hong, Hu Meng, Wei ZeHui, Zhang Dong, Zhang JunChang, Tian GuangJun. Bile formation, secretion, and excretion and the pathogenesis of cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 431-437. doi: 10.3969/j.issn.1001-5256.2019.02.043
    [12]Zhou Fang, Li XiaoQin, Wang RuiFeng, Sun Bo. X-linked lymphoproliferative disease type 2 with cholestatic liver disease as initial manifestation: A case report[J]. Journal of Clinical Hepatology, 2019, 35(8): 1811-1814. doi: 10.3969/j.issn.1001-5256.2019.08.034
    [13]Li XiaoFeng, Gong JingYu, Wang JianShe. Association between enterohepatic circulation of bile acid and cholestatic liver disease[J]. Journal of Clinical Hepatology, 2017, 33(10): 1922-1927. doi: 10.3969/j.issn.1001-5256.2017.10.014
    [14]Shen FeiFei, Lu LunGen. Liver alkaline phosphatase: a marker of cholestasis and bile duct injury[J]. Journal of Clinical Hepatology, 2016, 32(5): 1026-1030. doi: 10.3969/j.issn.1001-5256.2016.05.052
    [15]Li Hua, Li YiMing, Lu Le. Mechanism of α-naphthyl isothiocyanate inducing cholestatic hepatitis: a preliminary study[J]. Journal of Clinical Hepatology, 2016, 32(5): 933-937. doi: 10.3969/j.issn.1001-5256.2016.05.026
    [16]Zhang QiDi, Lu LunGen. Mechanisms and treatment of cholestasis- induced liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 337-341. doi: 10.3969/j.issn.1001-5256.2015.03.005
    [17]Qu Ying, Xu MingYi, Lu LunGen. Current progress in understanding of cholestasis and autoimmune liver diseases——Meeting review about 1st symposium on cholestasis and autoimmune liver disease[J]. Journal of Clinical Hepatology, 2011, 27(2): 222-225.
    [18]Yang Lu, Sun Mei. Clinical analysis of 145 cases with infantile cholestasis[J]. Journal of Clinical Hepatology, 2011, 27(7): 731-734.
    [19]Zhu QiRong, Wang JianShe. Differential diagnosis of infantile cholestasis[J]. Journal of Clinical Hepatology, 2011, 27(7): 679-681+693.
    [20]Lu LunGen. Mechanism of bile secretion, excretion, regulation and cholestasis[J]. Journal of Clinical Hepatology, 2011, 27(6): 570-571+580.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(1)

    1. 杨云，张国壮，刘婷，杨依霏. 探讨中药致胆汁淤积型肝损伤的特点及调控机制. 中国实验方剂学杂志. 2024(23): 64-71 .

    Other cited types(0)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 19.6 %FULLTEXT: 19.6 %META: 76.7 %META: 76.7 %PDF: 3.7 %PDF: 3.7 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 10.1 %其他: 10.1 %其他: 0.4 %其他: 0.4 %China: 0.1 %China: 0.1 %Russian Federation: 0.4 %Russian Federation: 0.4 %Tiruchi: 0.1 %Tiruchi: 0.1 %上海: 4.5 %上海: 4.5 %东京: 0.4 %东京: 0.4 %伊利诺伊州: 0.1 %伊利诺伊州: 0.1 %伦敦: 0.1 %伦敦: 0.1 %佛山: 0.2 %佛山: 0.2 %兰州: 0.1 %兰州: 0.1 %北京: 1.7 %北京: 1.7 %华盛顿州: 0.2 %华盛顿州: 0.2 %南京: 0.7 %南京: 0.7 %南宁: 0.1 %南宁: 0.1 %南昌: 0.1 %南昌: 0.1 %南通: 0.1 %南通: 0.1 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %台北: 0.1 %台北: 0.1 %合肥: 1.5 %合肥: 1.5 %呼和浩特: 0.1 %呼和浩特: 0.1 %咸阳: 0.1 %咸阳: 0.1 %唐山: 0.2 %唐山: 0.2 %天津: 0.2 %天津: 0.2 %威海: 0.4 %威海: 0.4 %孟买: 0.1 %孟买: 0.1 %安顺: 0.2 %安顺: 0.2 %常德: 0.4 %常德: 0.4 %广州: 0.7 %广州: 0.7 %廊坊: 0.1 %廊坊: 0.1 %弗吉: 0.1 %弗吉: 0.1 %张家口: 2.7 %张家口: 2.7 %成都: 0.1 %成都: 0.1 %斯基克达: 0.1 %斯基克达: 0.1 %新余: 0.1 %新余: 0.1 %旧金山: 0.1 %旧金山: 0.1 %杭州: 0.4 %杭州: 0.4 %格兰特县: 0.4 %格兰特县: 0.4 %沈阳: 0.2 %沈阳: 0.2 %洛杉矶: 0.1 %洛杉矶: 0.1 %洛阳: 0.1 %洛阳: 0.1 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.2 %海得拉巴: 0.2 %温州: 0.1 %温州: 0.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.5 %漯河: 0.5 %澳门: 0.1 %澳门: 0.1 %班加罗尔: 0.1 %班加罗尔: 0.1 %石家庄: 0.1 %石家庄: 0.1 %科泽科德: 0.1 %科泽科德: 0.1 %芒廷维尤: 36.1 %芒廷维尤: 36.1 %芝加哥: 3.7 %芝加哥: 3.7 %莫斯科: 0.9 %莫斯科: 0.9 %西宁: 14.7 %西宁: 14.7 %西安: 0.4 %西安: 0.4 %西雅图: 0.1 %西雅图: 0.1 %诺沃克: 0.2 %诺沃克: 0.2 %运城: 0.7 %运城: 0.7 %遵义: 0.1 %遵义: 0.1 %邯郸: 0.1 %邯郸: 0.1 %郑州: 0.9 %郑州: 0.9 %重庆: 0.4 %重庆: 0.4 %金奈: 0.1 %金奈: 0.1 %长春: 9.7 %长春: 9.7 %长沙: 0.5 %长沙: 0.5 %长治: 0.1 %长治: 0.1 %阿什本: 0.1 %阿什本: 0.1 %青岛: 0.4 %青岛: 0.4 %香港: 0.1 %香港: 0.1 %其他其他ChinaRussian FederationTiruchi上海东京伊利诺伊州伦敦佛山兰州北京华盛顿州南京南宁南昌南通卡纳塔克台北合肥呼和浩特咸阳唐山天津威海孟买安顺常德广州廊坊弗吉张家口成都斯基克达新余旧金山杭州格兰特县沈阳洛杉矶洛阳济南海得拉巴温州湘潭漯河澳门班加罗尔石家庄科泽科德芒廷维尤芝加哥莫斯科西宁西安西雅图诺沃克运城遵义邯郸郑州重庆金奈长春长沙长治阿什本青岛香港

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (619) PDF downloads(30) Cited by(1)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2740]YesterdayPV[5247]TodayIP[1439]TodayPV[2535]Online[90]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return